Advocacy intelligence hub — real-time data for patient organizations
Loma Linda University — NA
Jemincare — PHASE1
Jemincare — PHASE1
Richard Fatica — NA
Kenneth Hallows — PHASE2
Vertex Pharmaceuticals Incorporated — PHASE2
AstraZeneca — PHASE1
Jemincare — PHASE1
King's College London
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance2
Jynarque
Otsuka Pharmaceutical Company, Ltd.
Tolvaptan
Otsuka
Jynarque
(tolvaptan)Orphan drugOtsuka Pharmaceutical Company, Ltd.
Vasopressin V2 Receptor Antagonist [EPC]
12.1 Mechanism of Action Tolvaptan is a selective vasopressin V 2 -receptor antagonist with an affinity for the V 2 -receptor that is 1.8 times that o...
Browse all Autosomal dominant polycystic kidney disease news →
Michel B Chonchol, MD, MD
University of Colorado, Denver
📍 AURORA, CO
Melissa A Cadnapaphornchai, MD, MD
University of Colorado, Denver
📍 SAN ANTONIO, TX
Thomas Weimbs, PhD
Santa Barbara Nutrients
Meyeon Park, MD, MD
University of California, San Francisco
📍 SAN FRANCISCO, CA
Arlene Chapman, MD
Emory University
📍 KIMPER, KY
Robert W Schrier, MD, M.D
University of Colorado, Denver
📍 DELRAY BEACH, FL
View all Autosomal dominant polycystic kidney disease specialists →